A price that rises with the dose
Most sellers here promise the opposite: one price at every strength, so titrating up does not raise the bill. This one says plainly that its high-dose programmes cost more, and names the increment for each drug and the weekly milligram ceiling it buys.
That makes the two published figures floors, and we have said so in each qualifier. A buyer who titrates to the top of the range pays the programme rate plus the increment, every month, and can work that out in advance from the page. A seller that quietly re-quotes at month four is worse; a seller that publishes a flat rate and holds to it is better. This is the honest middle.
The research file that nominated this seller recorded a lower dose ceiling for one of the two drugs than the live page states. We re-read it rather than carrying it across.
The membership answer
Its own frequently-asked-questions block asks whether medication is included in the membership fee and answers yes, medications and supplies are included. Fourteen of the one hundred and fifty-eight sellers here publish a figure that already covers the medication.
It also states that no long-term contract is required. Between them those two answers make the programme figure a complete monthly bill at the standard dose, which is a clearer picture than most of this roster offers.
The warning letter
FDA wrote to this company in February 2026, having reviewed the website in December 2025, and found its claims about compounded semaglutide and tirzepatide false or misleading under the misbranding provisions of the Act.
Twenty-one of the one hundred and fifty-eight sellers here carry a warning letter. It is disclosed and it moves nothing here. It was found by searching the entity name; a search keyed to the seller's domain returns nothing, which is how a domain-based screen clears a roster it should not.
No compounding pharmacy is named — the page refers to an associate compounding pharmacy licensed in the buyer's state — and no individual clinician is named. No service area is published.
Premium Health's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $275/moper month for the semaglutide programme; the seller states its high-dose programme offering up to 2.4 mg a week costs an additional $100 a month, so this figure is a floor rather than a rate | September 2026source |
| Tirzepatide (compounded) | $445/moper month for the tirzepatide programme; the seller states its high-dose programme offering up to 15 mg a week costs an additional $150 a month, so this figure is a floor rather than a rate | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 158 providers reviewed here are paid partners today; the other 154 are not. See how this works.
See Premium Health's current price →Good fit if
- Readers who want to know what titrating up will cost before they start.
- Buyers who want the membership question answered in the seller's own FAQ, with the medication inside the fee.
- People who want a written statement that no long-term contract is required.
Look elsewhere if
- Anyone who wants one price at every dose. This seller charges more for the higher strengths and says so.
- Readers for whom an FDA warning letter about website claims is disqualifying.
- Buyers who want the compounding pharmacy or a clinician named, or a service-area list.
How this review was verified
- Re-read the weight-loss programme page on 6 September 2026, comparing the requested path to the effective path and running a nonsense path against the host in the same run.
- Read the dose ceilings and the surcharges off the live page rather than from the research file, which recorded a lower ceiling for one of the two drugs.
- Recorded both headline figures as floors, with the surcharge and the strength it buys written into each qualifier.
- Set the membership status from the seller's own FAQ answer rather than from a marketing line.
- Screened the entity name and the brand name against FDA's live warning-letter record with a positive and a negative control in the same pass, re-fetched the letter, and confirmed its title names this exact entity, number and date against a minted nonsense letter path that returned a not-found status in the same run. Untitled letters are published separately and were not searched.